1
|
A perivascular niche for brain tumor stem cells.
|
Cancer Cell
|
2007
|
11.55
|
2
|
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas.
|
Nat Genet
|
2012
|
7.61
|
3
|
Molecular subgroups of medulloblastoma: the current consensus.
|
Acta Neuropathol
|
2011
|
6.67
|
4
|
Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations.
|
J Clin Oncol
|
2006
|
5.96
|
5
|
Subtypes of medulloblastoma have distinct developmental origins.
|
Nature
|
2010
|
5.94
|
6
|
Radial glia cells are candidate stem cells of ependymoma.
|
Cancer Cell
|
2005
|
5.21
|
7
|
Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease.
|
J Clin Oncol
|
2010
|
4.94
|
8
|
Novel mutations target distinct subgroups of medulloblastoma.
|
Nature
|
2012
|
4.82
|
9
|
Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.
|
J Clin Oncol
|
2006
|
4.72
|
10
|
Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome.
|
J Clin Oncol
|
2010
|
4.48
|
11
|
Cross-species genomics matches driver mutations and cell compartments to model ependymoma.
|
Nature
|
2010
|
3.70
|
12
|
Late neurocognitive sequelae in survivors of brain tumours in childhood.
|
Lancet Oncol
|
2004
|
3.56
|
13
|
Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma.
|
J Clin Oncol
|
2011
|
3.56
|
14
|
Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas.
|
Nat Genet
|
2013
|
3.51
|
15
|
Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas.
|
J Pathol
|
2009
|
3.32
|
16
|
The miR-17~92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma.
|
Proc Natl Acad Sci U S A
|
2009
|
2.72
|
17
|
Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist.
|
Oncologist
|
2004
|
2.45
|
18
|
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation.
|
Clin Pharmacol Ther
|
2013
|
2.39
|
19
|
Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma.
|
J Clin Oncol
|
2005
|
2.34
|
20
|
Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis.
|
Lancet Oncol
|
2012
|
2.34
|
21
|
Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children's Oncology Group.
|
J Neurosurg
|
2006
|
2.31
|
22
|
Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy.
|
J Clin Oncol
|
2005
|
2.19
|
23
|
Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia.
|
Cancer
|
2005
|
1.93
|
24
|
Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors.
|
Cancer Cell
|
2009
|
1.92
|
25
|
Developmental model relating white matter volume to neurocognitive deficits in pediatric brain tumor survivors.
|
Cancer
|
2003
|
1.88
|
26
|
Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.
|
J Clin Oncol
|
2008
|
1.87
|
27
|
Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections.
|
Cancer Chemother Pharmacol
|
2014
|
1.78
|
28
|
An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma.
|
Cancer Cell
|
2011
|
1.78
|
29
|
High-grade astrocytoma in very young children.
|
Pediatr Blood Cancer
|
2007
|
1.77
|
30
|
ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma.
|
Clin Cancer Res
|
2003
|
1.71
|
31
|
Clinical and molecular characteristics of malignant transformation of low-grade glioma in children.
|
J Clin Oncol
|
2007
|
1.67
|
32
|
Processing speed, attention, and working memory after treatment for medulloblastoma: an international, prospective, and longitudinal study.
|
J Clin Oncol
|
2013
|
1.66
|
33
|
Outcome and prognostic features in pediatric gliomas: a review of 6212 cases from the Surveillance, Epidemiology, and End Results database.
|
Cancer
|
2009
|
1.57
|
34
|
Cytogenetic prognostication within medulloblastoma subgroups.
|
J Clin Oncol
|
2014
|
1.56
|
35
|
A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study.
|
J Neurooncol
|
2013
|
1.51
|
36
|
Phase I study of combination topotecan and carboplatin in pediatric solid tumors.
|
J Clin Oncol
|
2002
|
1.47
|
37
|
Predicting intellectual outcome among children treated with 35-40 Gy craniospinal irradiation for medulloblastoma.
|
Neuropsychology
|
2003
|
1.45
|
38
|
Atypical teratoid rhabdoid tumor: current therapy and future directions.
|
Front Oncol
|
2012
|
1.44
|
39
|
Modeling radiation dosimetry to predict cognitive outcomes in pediatric patients with CNS embryonal tumors including medulloblastoma.
|
Int J Radiat Oncol Biol Phys
|
2006
|
1.44
|
40
|
Understanding the cognitive impact on children who are treated for medulloblastoma.
|
J Pediatr Psychol
|
2007
|
1.42
|
41
|
Intellectual and functional outcome of children 3 years old or younger who have CNS malignancies.
|
J Clin Oncol
|
2005
|
1.39
|
42
|
Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study.
|
J Clin Oncol
|
2011
|
1.39
|
43
|
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
|
J Neurooncol
|
2006
|
1.38
|
44
|
Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420.
|
Clin Cancer Res
|
2007
|
1.35
|
45
|
Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report.
|
Clin Cancer Res
|
2007
|
1.34
|
46
|
Attention and memory functioning among pediatric patients with medulloblastoma.
|
J Pediatr Psychol
|
2005
|
1.31
|
47
|
Prospective collection of tissue samples at autopsy in children with diffuse intrinsic pontine glioma.
|
Cancer
|
2010
|
1.30
|
48
|
CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity.
|
Acta Neuropathol
|
2014
|
1.28
|
49
|
Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma.
|
J Clin Oncol
|
2010
|
1.27
|
50
|
Treatment outcomes in black and white children with cancer: results from the SEER database and St Jude Children's Research Hospital, 1992 through 2007.
|
J Clin Oncol
|
2012
|
1.25
|
51
|
Survival and long-term health and cognitive outcomes after low-grade glioma.
|
Neuro Oncol
|
2010
|
1.22
|
52
|
UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
|
J Clin Oncol
|
2007
|
1.20
|
53
|
Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961.
|
Neuro Oncol
|
2012
|
1.20
|
54
|
Atypical white matter volume development in children following craniospinal irradiation.
|
Neuro Oncol
|
2005
|
1.20
|
55
|
Abnormal hippocampal development in children with medulloblastoma treated with risk-adapted irradiation.
|
AJNR Am J Neuroradiol
|
2004
|
1.19
|
56
|
Young age may predict a better outcome for children with diffuse pontine glioma.
|
Cancer
|
2008
|
1.18
|
57
|
A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors.
|
Clin Cancer Res
|
2003
|
1.17
|
58
|
Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas.
|
Acta Neuropathol
|
2012
|
1.16
|
59
|
What's new in neuro-oncology? Recent advances in medulloblastoma.
|
Eur J Paediatr Neurol
|
2003
|
1.16
|
60
|
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy.
|
BMC Cancer
|
2014
|
1.14
|
61
|
Chemotherapy for malignant brain tumors of childhood.
|
J Child Neurol
|
2008
|
1.14
|
62
|
A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET.
|
Neuro Oncol
|
2008
|
1.13
|
63
|
Decline in corpus callosum volume among pediatric patients with medulloblastoma: longitudinal MR imaging study.
|
AJNR Am J Neuroradiol
|
2002
|
1.13
|
64
|
Second neoplasms in pediatric patients with primary central nervous system tumors: the St. Jude Children's Research Hospital experience.
|
Cancer
|
2004
|
1.13
|
65
|
Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group.
|
Acta Neuropathol
|
2013
|
1.12
|
66
|
Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98).
|
Cancer
|
2005
|
1.12
|
67
|
Physical performance limitations among adult survivors of childhood brain tumors.
|
Cancer
|
2010
|
1.12
|
68
|
Early patterns of verbal memory impairment in children treated for medulloblastoma.
|
Neuropsychology
|
2006
|
1.11
|
69
|
Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.
|
J Clin Oncol
|
2010
|
1.10
|
70
|
Survival and functional outcome of children with hypothalamic/chiasmatic tumors.
|
Cancer
|
2003
|
1.10
|
71
|
Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma.
|
Int J Radiat Oncol Biol Phys
|
2007
|
1.08
|
72
|
Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia.
|
Blood
|
2002
|
1.07
|
73
|
Clear cell ependymoma: a clinicopathologic and radiographic analysis of 10 patients.
|
Cancer
|
2003
|
1.06
|
74
|
Survival and late mortality in long-term survivors of pediatric CNS tumors.
|
J Clin Oncol
|
2007
|
1.05
|
75
|
Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial.
|
J Clin Oncol
|
2008
|
1.05
|
76
|
White matter integrity is associated with cognitive processing in patients treated for a posterior fossa brain tumor.
|
Neuro Oncol
|
2012
|
1.04
|
77
|
Proximal dentatothalamocortical tract involvement in posterior fossa syndrome.
|
Brain
|
2009
|
1.03
|
78
|
Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma.
|
Clin Cancer Res
|
2009
|
1.02
|
79
|
Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor.
|
J Clin Oncol
|
2004
|
1.02
|
80
|
White matter lesions detected by magnetic resonance imaging after radiotherapy and high-dose chemotherapy in children with medulloblastoma or primitive neuroectodermal tumor.
|
J Clin Oncol
|
2004
|
1.02
|
81
|
Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.
|
Clin Cancer Res
|
2002
|
1.01
|
82
|
Current therapy for medulloblastoma.
|
Curr Treat Options Neurol
|
2006
|
1.00
|
83
|
Intratumoral hemorrhage among children with newly diagnosed, diffuse brainstem glioma.
|
Cancer
|
2006
|
0.99
|
84
|
Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001).
|
J Clin Oncol
|
2005
|
0.98
|
85
|
Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
|
Neuro Oncol
|
2013
|
0.98
|
86
|
Chromosome 17 abnormalities in pediatric neuroblastic tumor with abundant neuropil and true rosettes.
|
Am J Clin Pathol
|
2006
|
0.97
|
87
|
High-dose chemotherapy with autologous stem cell rescue for children with recurrent malignant brain tumors.
|
Cancer
|
2008
|
0.97
|
88
|
Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study.
|
Cancer
|
2006
|
0.97
|
89
|
Diffusion tensor imaging of intraaxial tumors at the cervicomedullary and pontomedullary junctions. Report of two cases.
|
J Neurosurg
|
2005
|
0.97
|
90
|
Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the Children's Oncology Group.
|
Neuro Oncol
|
2013
|
0.97
|
91
|
MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas.
|
Acta Neuropathol
|
2010
|
0.96
|
92
|
Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.
|
Cancer
|
2008
|
0.95
|
93
|
Molecular biology of medulloblastoma: will it ever make a difference to clinical management?
|
J Neurooncol
|
2005
|
0.95
|
94
|
Sequencing of local therapy affects the pattern of treatment failure and survival in children with atypical teratoid rhabdoid tumors of the central nervous system.
|
Int J Radiat Oncol Biol Phys
|
2011
|
0.95
|
95
|
Abnormal timing of menarche in survivors of central nervous system tumors: A report from the Childhood Cancer Survivor Study.
|
Cancer
|
2009
|
0.93
|
96
|
Population pharmacokinetic analysis of topotecan in pediatric cancer patients.
|
Clin Cancer Res
|
2007
|
0.93
|
97
|
Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study.
|
Neuro Oncol
|
2012
|
0.92
|
98
|
Clinico-radiologic characteristics of long-term survivors of diffuse intrinsic pontine glioma.
|
J Neurooncol
|
2013
|
0.91
|
99
|
Mutational analysis of PDGFR-RAS/MAPK pathway activation in childhood medulloblastoma.
|
Eur J Cancer
|
2006
|
0.91
|
100
|
Successful treatment of early detected trilateral retinoblastoma using standard infant brain tumor therapy.
|
Pediatr Blood Cancer
|
2010
|
0.91
|
101
|
Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors.
|
Cancer Chemother Pharmacol
|
2003
|
0.91
|
102
|
Differences in brainstem fiber tract response to radiation: a longitudinal diffusion tensor imaging study.
|
Int J Radiat Oncol Biol Phys
|
2013
|
0.91
|
103
|
Brain tumor therapy-induced changes in normal-appearing brainstem measured with longitudinal diffusion tensor imaging.
|
Int J Radiat Oncol Biol Phys
|
2011
|
0.90
|
104
|
Neurocognitive outcome 12 months following cerebellar mutism syndrome in pediatric patients with medulloblastoma.
|
Neuro Oncol
|
2010
|
0.89
|
105
|
Diffusion tensor imaging of brainstem tumors: axonal degeneration of motor and sensory tracts.
|
J Neurosurg Pediatr
|
2008
|
0.88
|
106
|
Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.
|
Clin Cancer Res
|
2013
|
0.88
|
107
|
New chemotherapy strategies and biological agents in the treatment of childhood ependymoma.
|
Childs Nerv Syst
|
2009
|
0.88
|
108
|
A knowledge-guided active contour method of segmentation of cerebella on MR images of pediatric patients with medulloblastoma.
|
J Magn Reson Imaging
|
2005
|
0.88
|
109
|
Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in children.
|
Cancer Chemother Pharmacol
|
2005
|
0.87
|
110
|
M1 Medulloblastoma: high risk at any age.
|
J Neurooncol
|
2008
|
0.87
|
111
|
Diagnostic utility and correlation of tumor markers in the serum and cerebrospinal fluid of children with intracranial germ cell tumors.
|
Childs Nerv Syst
|
2012
|
0.86
|
112
|
Hemodynamic responses to visual stimulation in children with sickle cell anemia.
|
Brain Imaging Behav
|
2011
|
0.86
|
113
|
Quantitative morphologic evaluation of white matter in survivors of childhood medulloblastoma.
|
Magn Reson Imaging
|
2006
|
0.85
|
114
|
Parent-reported social outcomes after treatment for pediatric embryonal tumors: a prospective longitudinal study.
|
J Clin Oncol
|
2012
|
0.85
|
115
|
Current treatment options for pediatric and adult patients with ependymoma.
|
Curr Treat Options Oncol
|
2012
|
0.84
|
116
|
Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system.
|
Brain Pathol
|
2013
|
0.84
|
117
|
Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma.
|
Neuro Oncol
|
2006
|
0.84
|
118
|
Pilot study of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial central nervous system tumors: a pediatric brain tumor consortium study (PBTC-001).
|
J Neurooncol
|
2012
|
0.83
|
119
|
Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).
|
Cancer
|
2013
|
0.83
|
120
|
Clinically evident venous thromboembolic events in children with brain tumors.
|
J Pediatr
|
2004
|
0.82
|
121
|
Seizures in children with primary brain tumors: incidence and long-term outcome.
|
Epilepsy Res
|
2005
|
0.82
|
122
|
Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia.
|
J Clin Oncol
|
2003
|
0.82
|
123
|
Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma.
|
Clin Cancer Res
|
2010
|
0.82
|
124
|
High-dose chemotherapy for recurrent medulloblastoma: time for a reappraisal.
|
Cancer
|
2008
|
0.82
|
125
|
Fanconi anemia and biallelic BRCA2 mutation diagnosed in a young child with an embryonal CNS tumor.
|
Pediatr Blood Cancer
|
2009
|
0.82
|
126
|
An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN).
|
J Neurooncol
|
2015
|
0.82
|
127
|
Regional white matter anisotropy and reading ability in patients treated for pediatric embryonal tumors.
|
Brain Imaging Behav
|
2010
|
0.81
|
128
|
Intellectual and academic outcome following two chemotherapy regimens and radiotherapy for average-risk medulloblastoma: COG A9961.
|
Pediatr Blood Cancer
|
2013
|
0.81
|
129
|
How parents cope with their child's diagnosis and treatment of an embryonal tumor: results of a prospective and longitudinal study.
|
J Neurooncol
|
2011
|
0.81
|
130
|
Carboplatin-based primary chemotherapy for infants and young children with CNS tumors.
|
Cancer
|
2009
|
0.81
|
131
|
Management and outcome of focal low-grade brainstem tumors in pediatric patients: the St. Jude experience.
|
J Neurosurg Pediatr
|
2013
|
0.80
|
132
|
Isochromosome 17q, MYC amplification and large cell/anaplastic phenotype in a case of medullomyoblastoma with extracranial metastases.
|
Pediatr Blood Cancer
|
2011
|
0.80
|
133
|
Reirradiation of recurrent medulloblastoma: does clinical benefit outweigh risk for toxicity?
|
Cancer
|
2014
|
0.80
|
134
|
Characterization, treatment, and outcome of intracranial neoplasms in the first 120 days of life.
|
J Child Neurol
|
2011
|
0.80
|
135
|
Feasibility and efficacy of a computer-based intervention aimed at preventing reading decoding deficits among children undergoing active treatment for medulloblastoma: results of a randomized trial.
|
J Pediatr Psychol
|
2013
|
0.79
|
136
|
Magnetic resonance imaging is the preferred method to assess treatment-related skeletal changes in children with brain tumors.
|
Pediatr Blood Cancer
|
2013
|
0.79
|
137
|
Radiation therapy and adjuvant chemotherapy in a patient with a malignant glioneuronal tumor and underlying ataxia telangiectasia: a case report and review of the literature.
|
J Clin Oncol
|
2012
|
0.79
|
138
|
Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC.
|
Cancer Chemother Pharmacol
|
2005
|
0.79
|
139
|
The use of bone age for bone mineral density interpretation in a cohort of pediatric brain tumor patients.
|
Pediatr Radiol
|
2008
|
0.79
|
140
|
Central neurogenic hyperventilation and renal tubular acidosis in children with pontine gliomas.
|
Neurology
|
2014
|
0.78
|
141
|
Necrosis after craniospinal irradiation: results from a prospective series of children with central nervous system embryonal tumors.
|
Int J Radiat Oncol Biol Phys
|
2012
|
0.78
|
142
|
Sleep disturbances in adult survivors of childhood brain tumors.
|
Qual Life Res
|
2012
|
0.78
|
143
|
Molecular characteristics of pediatric high-grade gliomas.
|
CNS Oncol
|
2014
|
0.78
|
144
|
Radiation therapy quality in CCG/POG intergroup 9961: implications for craniospinal irradiation and the posterior fossa boost in future medulloblastoma trials.
|
Front Oncol
|
2012
|
0.77
|
145
|
Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma.
|
Pediatr Blood Cancer
|
2013
|
0.77
|
146
|
Dysembryoplastic neuroepithelial tumors and cognitive outcome: cure at a price?
|
Cancer
|
2010
|
0.77
|
147
|
Cumulative cisplatin dose is not associated with event-free or overall survival in children with newly diagnosed average-risk medulloblastoma treated with cisplatin based adjuvant chemotherapy: report from the Children's Oncology Group.
|
Pediatr Blood Cancer
|
2013
|
0.77
|
148
|
Delayed diagnosis of childhood low-grade glioma: causes, consequences, and potential solutions.
|
Childs Nerv Syst
|
2015
|
0.77
|
149
|
Corrigendum: Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss.
|
Nat Genet
|
2015
|
0.77
|
150
|
Restricted access to the environment and quality of life in adult survivors of childhood brain tumors.
|
J Neurooncol
|
2012
|
0.76
|
151
|
Effect of time from diagnosis to start of radiotherapy on children with diffuse intrinsic pontine glioma.
|
Pediatr Blood Cancer
|
2014
|
0.75
|
152
|
Stability of cyclophosphamide in extemporaneous oral suspensions.
|
Ann Pharmacother
|
2010
|
0.75
|
153
|
Incidental diagnosis of diffuse intrinsic pontine glioma in children.
|
Pediatr Blood Cancer
|
2015
|
0.75
|
154
|
Benefit from prolonged dose-intensive chemotherapy for infants with malignant brain tumors is restricted to patients with ependymoma: a report of the Pediatric Oncology Group randomized controlled trial 9233/34.
|
Neuro Oncol
|
2013
|
0.75
|
155
|
Constraint-Induced Movement Therapy for Children With Brain Tumors.
|
Pediatr Phys Ther
|
2017
|
0.75
|
156
|
Prognostic value and functional consequences of cell cycle inhibitor p27Kip1 loss in medulloblastoma.
|
Biomark Res
|
2013
|
0.75
|
157
|
Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study.
|
Childs Nerv Syst
|
2015
|
0.75
|
158
|
Ocular neuromyotonia: video case report.
|
Neurology
|
2006
|
0.75
|
159
|
896 Anatomic Variants of Ependymoma Arise from Distinct Subsets of Radial Glial Cells.
|
Neurosurgery
|
2005
|
0.75
|
160
|
Medulloblastoma metastatic to the suprasellar region at diagnosis: a report of six cases with clinicopathologic correlation.
|
Pediatr Neurosurg
|
2002
|
0.75
|